The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria

Beatrice Wobiarueri Moore-Igwe; Ransom Baribefii Jacob; Serekara Gideon Christian; Evelyn Mgbeoma Eze

doi:doi:10.11648/j.iji.20221001.12

| Peer-Reviewed

The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria

Beatrice Wobiarueri Moore-Igwe, Ransom Baribefii Jacob, Serekara Gideon Christian, Evelyn Mgbeoma Eze

Published in International Journal of Immunology (Volume 10, Issue 1)

Received: 17 February 2022 Accepted: 15 March 2022 Published: 31 May 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: In other to enhance immune response and remove completely the danger of disease associated with AIDS, commencement of combination Antiretroviral Therapy (cART) is advocated. Common among HIV positive subjects are diseases such as cardiovascular conditions among others which happen when there is distortion in the gut mucosa, existence of co-infections, and long-term cART effect which gives room to vicious cycle that impairs on immune activities and inflammation. Inflammatory predictors which reveal the danger of morbidity and mortality are raised in HIV disease. A novel marker for inflammation – Platelet/Lymphocyte ratio (PLR), is a prognostic tool for assessing inflammation, atherosclerosis and platelet activation. Aim: This study was aimed at assessing prospectively, cART effect on the PLR and coagulation indices in HIV positive subjects presenting to commence cART in Rivers State University Teaching Hospital. Methods: Six milliliters of venous blood was collected from each participants into EDTA bottles at entry into the study, after 3 months and 6 months on cART respectively for Full Blood Count using a 3-part Sysmex XP300 and HIV Viral Load using RT-PCR Cobas TaqMan version 1.5 Results: A total of 40 subjects were recruited, with a mean age of 36.20 years, 14 (35%) of them were males. Mean PCV, Platelet: Lymphocyte ratio and HIV VL at Month 0 were 31.65±7.30%, 7.82±2.90 and 215767.85 ± 360338.04cp/ml respectively. There was a statistically significant increase (p <0.001) in the haematocrit by the 6^th month on cART, the reduction in Platelet: Lymphocyte count and of HIV VL by the 6^th month was also significant (P<0.001). Interestingly, PLR positively correlated with the VL at baseline (0.3676), however, there was a negative correlation at 3 months (-0125) and 6 months (-0.028). Conclusion: From this work it is clear that all the cases in this regard, confirm the fact that cART remarkably drops the viral load and inflammation in HIV positive subjects; nevertheless, it also shows that a low-level inflammation continues which probably leads to chronic inflammatory state, morbidity and mortality in this group of subjects.

Published in	International Journal of Immunology (Volume 10, Issue 1)
DOI	10.11648/j.iji.20221001.12
Page(s)	5-10
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Platelet/Lymphocyte Ratio (NLR), Combined Antiretroviral Therapy (cART), Human Immunodeficiency Virus (HIV), Viral Load (VL)

References

[1]	Freiberg, M. S., Chang, C. C., Kuller, L. H., Skanderson, M, Lowy E, Kraemer, K. L., Butt, A. A., Bidwell, G. M., Leaf, D. & Oursler, K. A. (2013). HIV infection and the risk of acute Myocardial Infarction. Journal of the American Medical Association 173, 614–622.
[2]	Cushman, M., Lemaitre, R. N., Kuller, L. H., Psaty, B. M., Macy, E. M., Sharrett, A. R. & Tracy, R. P. (1999). Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arteriosclerosis, Thrombosis and Vascular Biology, 19, 493–498.
[3]	Kuller, L. H., Tracy, R., Belloso, W., De Wit, S., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J. & Nixon, D. (2008). Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. The Public Library of Science (PLOS) Medicine, 5, 203.
[4]	Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. (2010). Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 55 (3): 316–322.
[5]	Rhew, D. C., Bernal, M., Aguilar, D., Iloeje, U. & Goetz, M. B. (2003). Association between protease inhibitor rise and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Journal of Clinical and Infectious Disease, 37 (7), 959–972.
[6]	Mocroft, A., Lundgren, J. D., Sabin, M. L., Monforte, A., Brockmeyer, N. & Casabona, J. (2013). Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) Plos Medicine, 10 (9), 10.
[7]	Rönsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. (2013). Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. Plos One. 8 (6): e65182.
[8]	Calmy, A., Gayet-Ageron, A., Montecucco, F., Nguyen, A., Mach, F., Burger, F., Ubolyam S., Carr, A., Ruxungtham, K., Hirschel, B. & Anan, J. (2009). HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS, 23, 929–939.
[9]	Jong, E., Louw, S., Meijers, J. C., de Kruif, M. D., ten Cate, H., Buller, H. R., Mulder, J. W. & Van - Gorp, E. C. (2009). The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: Partial restoration with antiretroviral therapy. AIDS Patient Care STDS, 23, 1001–1007.
[10]	Palella, F. J. Jr., Gange, S. J., Benning, L., Jacobson, L., Kaplan, R. C., Landay, A. L., Tracy, R. P. & Elion, R. (2010). Inflammatory biomarkers and abacavir use in the Women’s Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS, 24, 1657–1665.
[11]	Duprez, D. A., Neuhaus, J., Kuller, L. H., Tracy, R., Belloso, W., De Wit. S., Drummond, F., Lane, H. C., Ledergerber, B. & Lundgren, J. (2012). Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One, 7 (9), 20.
[12]	Ford, E. S., Greenwald, J. H., Richterman, A. G., Rupert, A., Dutcher, L., Badralmaa, Y., Natarajan, V., Rehm, C., Hadigan, C. & Sereti, I. (2010). Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS, 24, 1509–1517.
[13]	Ledwaba, L., Tavel, J. A., Khabo, P., Maja, P., Qin, J., Sangweni, P., Liu, X., Follmann, D., Metcalf, J. A. & Orsega S. (2012). Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. The Public Library of Science (PLOS), 7, 24243.
[14]	Musselwhite, L. W., Sheikh, V., Norton, T. D., Rupert, A., Porter, B. O., Penzak, S. R., Skinner, J., Mican, J. M., Hadigan, C. & Sereti, I. (2011). Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS, 25, 787–795.
[15]	Raffetti, E., Francesco, D., Salvatore, C., Filippo, C., Laura, S., Alessandra, B., Franco, M., Nicoletta, L., Massimo, D., Chiara, F., Simona, D. & Eugenia, Q. (2017). Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. Biomed Central Infectious Diseases, 17, 193.
[16]	Templeton, A. J., Ace, O., Mcnamara, M. G., Al-Mubarak, M., Vera, F. E. & Hermanns, T. (2014). Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 23 (7), 1204–1212.
[17]	Wu, Y., Chen, Y., Yang, X., Chen, L. & Yang, Y. (2016). Neutrophil – to – lymphocyte ratio (NLR) and platelet – to – lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupusery the matosus. International Immunopharmacology Journal, 36, 94–99.
[18]	Fu, H., Qin, B., Hu, Z., Ma, N., Yang, M. & Wei, T. (2015). Neutrophil and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clinical Laboratory, 61 (3-4), 269–273.
[19]	Mattia, G., Vulcano, F., Milazzo, L., Barca, A., Macioce, G. & Giampaolo, A. (2002). Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood, 99 (3), 888–897.
[20]	Oncel, M. Y., Ozdemir, R., Yurttutan, S., Canpolat, F. E., Erdeve, O., Oguz, S. S. (2012). Mean platelet volume in neonatal sepsis. Journal of Clinical Laboratory Analysis, 26 (6), 493–496.
[21]	Artunc, U. B., Pala, H. G., Calik, E. & Oruc, K. S. (2014). Platelet distribution width (PDW): A putative marker for threatened preterm labour. Pakistan Journal of Medical Science, 30 (4), 745–748.
[22]	Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, et al. (2013). Platelet count kinetics following interruption of antiretroviral treatment. AIDS. 27: 59–68.
[23]	Li, W., Liu, Q. & Tang, Y. (2017). Platelet to lymphocyte ratio in the prediction of adverse out comes after acute coronary syndrome: A meta-analysis. International Journal of Scientific Report, 7, 40426.
[24]	Wang, Q., Ma, J., Jiang, Z. & Ming, L. (2018). Prognostic value of neutrophil -to-lymphocyte ratio and platelet – to – lymphocyte ratio in acute pulmonary embolism: A systematic review and meta-analysis. International Angiology, 37, 4-11.
[25]	Borges, Á. H., Silverberg, M. J., Wentworth, D., Grulich, A. E., Fätkenheuer, G. & Mitsuyasu, R. (2013). Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation bio-markers. AIDS, 27, 1433–1441.
[26]	Kawasaky, T., Dewerchin, M., Lijnen, H. R., Vermylen, J. & Hoylaerts, M. F. (2000). Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood, 96, 153–60.
[27]	Eugenia, Q., Paola, M., Elena, R., Ilaria, I., Alessandro, B., Francesca, L., Annalisa, S., Franco, M. & Francesco, C. (2018). Master Cohort BMC Infectious Diseases, 18, 285.
[28]	Moore-Igwe, B. W., Omunakwe H. E., Ibegbulem E. O., Eze E. N. & Jeremiah Z. A. (2018a). Viral load monitoring and fibrinolytic markers in human Immunodeficiency virus infected patients on antiretroviral therapy. European Journal of Biomedical and Pharmaceutical sciences, 5 (12), 98-110.
[29]	Moore-Igwe, B. W., Omunakwe H. E., Ibegbulem E. O., Eze E. N. & Jeremiah, Z. A. (2018b). Viral Load Monitoring and Haematological Parameters in Human Immunodeficiency Virus patients on Antiretroviral Therapy. International Journal of Current Research in Biology and Medicine, 3 (11) 4-14.
[30]	Chukwurah, F. E., Echeobi, D. & Nneli, R. O. (2007). Haematological profile of human immunodeficient (HIV) seropositive patients on antiretroviral (ARV) therapy: Implication of nutrition. Research Journal of Medical Science, 1, 242-244.
[31]	Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A. & Emini, H. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122.
[32]	Blockman, D. (1991). HIV related thrombocytopenia. British Journal of Haematological, 99, 350-354.

Cite This Article

Plain Text BibTeX RIS

APA Style

Beatrice Wobiarueri Moore-Igwe, Ransom Baribefii Jacob, Serekara Gideon Christian, Evelyn Mgbeoma Eze. (2022). The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. International Journal of Immunology, 10(1), 5-10. https://doi.org/10.11648/j.iji.20221001.12

Copy | Download

ACS Style

Beatrice Wobiarueri Moore-Igwe; Ransom Baribefii Jacob; Serekara Gideon Christian; Evelyn Mgbeoma Eze. The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. Int. J. Immunol. 2022, 10(1), 5-10. doi: 10.11648/j.iji.20221001.12

Copy | Download

AMA Style

Beatrice Wobiarueri Moore-Igwe, Ransom Baribefii Jacob, Serekara Gideon Christian, Evelyn Mgbeoma Eze. The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. Int J Immunol. 2022;10(1):5-10. doi: 10.11648/j.iji.20221001.12

Copy | Download

@article{10.11648/j.iji.20221001.12,
  author = {Beatrice Wobiarueri Moore-Igwe and Ransom Baribefii Jacob and Serekara Gideon Christian and Evelyn Mgbeoma Eze},
  title = {The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria},
  journal = {International Journal of Immunology},
  volume = {10},
  number = {1},
  pages = {5-10},
  doi = {10.11648/j.iji.20221001.12},
  url = {https://doi.org/10.11648/j.iji.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20221001.12},
  abstract = {Background: In other to enhance immune response and remove completely the danger of disease associated with AIDS, commencement of combination Antiretroviral Therapy (cART) is advocated. Common among HIV positive subjects are diseases such as cardiovascular conditions among others which happen when there is distortion in the gut mucosa, existence of co-infections, and long-term cART effect which gives room to vicious cycle that impairs on immune activities and inflammation. Inflammatory predictors which reveal the danger of morbidity and mortality are raised in HIV disease. A novel marker for inflammation – Platelet/Lymphocyte ratio (PLR), is a prognostic tool for assessing inflammation, atherosclerosis and platelet activation. Aim: This study was aimed at assessing prospectively, cART effect on the PLR and coagulation indices in HIV positive subjects presenting to commence cART in Rivers State University Teaching Hospital. Methods: Six milliliters of venous blood was collected from each participants into EDTA bottles at entry into the study, after 3 months and 6 months on cART respectively for Full Blood Count using a 3-part Sysmex XP300 and HIV Viral Load using RT-PCR Cobas TaqMan version 1.5 Results: A total of 40 subjects were recruited, with a mean age of 36.20 years, 14 (35%) of them were males. Mean PCV, Platelet: Lymphocyte ratio and HIV VL at Month 0 were 31.65±7.30%, 7.82±2.90 and 215767.85 ± 360338.04cp/ml respectively. There was a statistically significant increase (p th month on cART, the reduction in Platelet: Lymphocyte count and of HIV VL by the 6th month was also significant (PConclusion: From this work it is clear that all the cases in this regard, confirm the fact that cART remarkably drops the viral load and inflammation in HIV positive subjects; nevertheless, it also shows that a low-level inflammation continues which probably leads to chronic inflammatory state, morbidity and mortality in this group of subjects.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria
AU  - Beatrice Wobiarueri Moore-Igwe
AU  - Ransom Baribefii Jacob
AU  - Serekara Gideon Christian
AU  - Evelyn Mgbeoma Eze
Y1  - 2022/05/31
PY  - 2022
N1  - https://doi.org/10.11648/j.iji.20221001.12
DO  - 10.11648/j.iji.20221001.12
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 5
EP  - 10
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20221001.12
AB  - Background: In other to enhance immune response and remove completely the danger of disease associated with AIDS, commencement of combination Antiretroviral Therapy (cART) is advocated. Common among HIV positive subjects are diseases such as cardiovascular conditions among others which happen when there is distortion in the gut mucosa, existence of co-infections, and long-term cART effect which gives room to vicious cycle that impairs on immune activities and inflammation. Inflammatory predictors which reveal the danger of morbidity and mortality are raised in HIV disease. A novel marker for inflammation – Platelet/Lymphocyte ratio (PLR), is a prognostic tool for assessing inflammation, atherosclerosis and platelet activation. Aim: This study was aimed at assessing prospectively, cART effect on the PLR and coagulation indices in HIV positive subjects presenting to commence cART in Rivers State University Teaching Hospital. Methods: Six milliliters of venous blood was collected from each participants into EDTA bottles at entry into the study, after 3 months and 6 months on cART respectively for Full Blood Count using a 3-part Sysmex XP300 and HIV Viral Load using RT-PCR Cobas TaqMan version 1.5 Results: A total of 40 subjects were recruited, with a mean age of 36.20 years, 14 (35%) of them were males. Mean PCV, Platelet: Lymphocyte ratio and HIV VL at Month 0 were 31.65±7.30%, 7.82±2.90 and 215767.85 ± 360338.04cp/ml respectively. There was a statistically significant increase (p th month on cART, the reduction in Platelet: Lymphocyte count and of HIV VL by the 6th month was also significant (PConclusion: From this work it is clear that all the cases in this regard, confirm the fact that cART remarkably drops the viral load and inflammation in HIV positive subjects; nevertheless, it also shows that a low-level inflammation continues which probably leads to chronic inflammatory state, morbidity and mortality in this group of subjects.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Beatrice Wobiarueri Moore-Igwe

Department of Medical Laboratory Science, Rivers State University, Port-Harcourt, Nigeria
Ransom Baribefii Jacob

Department of Medical Laboratory Science, Rivers State University, Port-Harcourt, Nigeria
Serekara Gideon Christian

Department of Medical Laboratory Science, Rivers State University, Port-Harcourt, Nigeria
Evelyn Mgbeoma Eze

Department of Medical Laboratory Science, Rivers State University, Port-Harcourt, Nigeria

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Beatrice Wobiarueri Moore-Igwe, Ransom Baribefii Jacob, Serekara Gideon Christian, Evelyn Mgbeoma Eze. (2022). The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. International Journal of Immunology, 10(1), 5-10. https://doi.org/10.11648/j.iji.20221001.12

Copy | Download

ACS Style

Beatrice Wobiarueri Moore-Igwe; Ransom Baribefii Jacob; Serekara Gideon Christian; Evelyn Mgbeoma Eze. The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. Int. J. Immunol. 2022, 10(1), 5-10. doi: 10.11648/j.iji.20221001.12

Copy | Download

AMA Style

Beatrice Wobiarueri Moore-Igwe, Ransom Baribefii Jacob, Serekara Gideon Christian, Evelyn Mgbeoma Eze. The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria. Int J Immunol. 2022;10(1):5-10. doi: 10.11648/j.iji.20221001.12

Copy | Download

@article{10.11648/j.iji.20221001.12,
  author = {Beatrice Wobiarueri Moore-Igwe and Ransom Baribefii Jacob and Serekara Gideon Christian and Evelyn Mgbeoma Eze},
  title = {The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria},
  journal = {International Journal of Immunology},
  volume = {10},
  number = {1},
  pages = {5-10},
  doi = {10.11648/j.iji.20221001.12},
  url = {https://doi.org/10.11648/j.iji.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20221001.12},
  abstract = {Background: In other to enhance immune response and remove completely the danger of disease associated with AIDS, commencement of combination Antiretroviral Therapy (cART) is advocated. Common among HIV positive subjects are diseases such as cardiovascular conditions among others which happen when there is distortion in the gut mucosa, existence of co-infections, and long-term cART effect which gives room to vicious cycle that impairs on immune activities and inflammation. Inflammatory predictors which reveal the danger of morbidity and mortality are raised in HIV disease. A novel marker for inflammation – Platelet/Lymphocyte ratio (PLR), is a prognostic tool for assessing inflammation, atherosclerosis and platelet activation. Aim: This study was aimed at assessing prospectively, cART effect on the PLR and coagulation indices in HIV positive subjects presenting to commence cART in Rivers State University Teaching Hospital. Methods: Six milliliters of venous blood was collected from each participants into EDTA bottles at entry into the study, after 3 months and 6 months on cART respectively for Full Blood Count using a 3-part Sysmex XP300 and HIV Viral Load using RT-PCR Cobas TaqMan version 1.5 Results: A total of 40 subjects were recruited, with a mean age of 36.20 years, 14 (35%) of them were males. Mean PCV, Platelet: Lymphocyte ratio and HIV VL at Month 0 were 31.65±7.30%, 7.82±2.90 and 215767.85 ± 360338.04cp/ml respectively. There was a statistically significant increase (p th month on cART, the reduction in Platelet: Lymphocyte count and of HIV VL by the 6th month was also significant (PConclusion: From this work it is clear that all the cases in this regard, confirm the fact that cART remarkably drops the viral load and inflammation in HIV positive subjects; nevertheless, it also shows that a low-level inflammation continues which probably leads to chronic inflammatory state, morbidity and mortality in this group of subjects.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Effect of cART on Platelets/Lymphocytes Ratio and Viral Load Indices in HIV+ Subjects Initiating Therapy in a Tertiary Hospital in Port Harcourt, Nigeria
AU  - Beatrice Wobiarueri Moore-Igwe
AU  - Ransom Baribefii Jacob
AU  - Serekara Gideon Christian
AU  - Evelyn Mgbeoma Eze
Y1  - 2022/05/31
PY  - 2022
N1  - https://doi.org/10.11648/j.iji.20221001.12
DO  - 10.11648/j.iji.20221001.12
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 5
EP  - 10
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20221001.12
AB  - Background: In other to enhance immune response and remove completely the danger of disease associated with AIDS, commencement of combination Antiretroviral Therapy (cART) is advocated. Common among HIV positive subjects are diseases such as cardiovascular conditions among others which happen when there is distortion in the gut mucosa, existence of co-infections, and long-term cART effect which gives room to vicious cycle that impairs on immune activities and inflammation. Inflammatory predictors which reveal the danger of morbidity and mortality are raised in HIV disease. A novel marker for inflammation – Platelet/Lymphocyte ratio (PLR), is a prognostic tool for assessing inflammation, atherosclerosis and platelet activation. Aim: This study was aimed at assessing prospectively, cART effect on the PLR and coagulation indices in HIV positive subjects presenting to commence cART in Rivers State University Teaching Hospital. Methods: Six milliliters of venous blood was collected from each participants into EDTA bottles at entry into the study, after 3 months and 6 months on cART respectively for Full Blood Count using a 3-part Sysmex XP300 and HIV Viral Load using RT-PCR Cobas TaqMan version 1.5 Results: A total of 40 subjects were recruited, with a mean age of 36.20 years, 14 (35%) of them were males. Mean PCV, Platelet: Lymphocyte ratio and HIV VL at Month 0 were 31.65±7.30%, 7.82±2.90 and 215767.85 ± 360338.04cp/ml respectively. There was a statistically significant increase (p th month on cART, the reduction in Platelet: Lymphocyte count and of HIV VL by the 6th month was also significant (PConclusion: From this work it is clear that all the cases in this regard, confirm the fact that cART remarkably drops the viral load and inflammation in HIV positive subjects; nevertheless, it also shows that a low-level inflammation continues which probably leads to chronic inflammatory state, morbidity and mortality in this group of subjects.
VL  - 10
IS  - 1
ER  -

Copy | Download